Follow
Yuval Shaked
Yuval Shaked
Verified email at technion.ac.il - Homepage
Title
Cited by
Cited by
Year
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
F Bertolini, Y Shaked, P Mancuso, RS Kerbel
Nature Reviews Cancer 6 (11), 835-845, 2006
7272006
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Y Shaked, A Ciarrocchi, M Franco, CR Lee, S Man, AM Cheung, ...
Science 313 (5794), 1785-1787, 2006
6762006
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
F Bertolini, S Paul, P Mancuso, S Monestiroli, A Gobbi, Y Shaked, ...
Cancer research 63 (15), 4342-4346, 2003
6182003
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ...
Cancer cell 14 (3), 263-273, 2008
5262008
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
C Folkins, S Man, P Xu, Y Shaked, DJ Hicklin, RS Kerbel
Cancer research 67 (8), 3560-3564, 2007
4782007
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis
Y Shaked, F Bertolini, S Man, MS Rogers, D Cervi, T Foutz, K Rawn, ...
Cancer cell 7 (1), 101-111, 2005
4622005
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1
C Folkins, Y Shaked, S Man, T Tang, CR Lee, Z Zhu, RM Hoffman, ...
Cancer research 69 (18), 7243-7251, 2009
4112009
Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia
M Bosch-Marce, H Okuyama, JB Wesley, K Sarkar, H Kimura, YV Liu, ...
Circulation research 101 (12), 1310-1318, 2007
3752007
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
S Dellapasqua, F Bertolini, V Bagnardi, E Campagnoli, E Scarano, ...
Journal of Clinical Oncology 26 (30), 4899-4905, 2008
3372008
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Y Shaked, U Emmenegger, S Man, D Cervi, F Bertolini, Y Ben-David, ...
Blood 106 (9), 3058-3061, 2005
3172005
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
P Mancuso, M Colleoni, A Calleri, L Orlando, P Maisonneuve, G Pruneri, ...
Blood 108 (2), 452-459, 2006
3012006
A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases
GM Shaked, Y Shaked, Z Kariv-Inbal, M Halimi, I Avraham, R Gabizon
Journal of Biological Chemistry 276 (34), 31479-31482, 2001
2712001
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
JLG Bender, PC Adamson, JM Reid, L Xu, S Baruchel, Y Shaked, ...
Journal of clinical oncology 26 (3), 399-405, 2008
2682008
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy
R Munoz, S Man, Y Shaked, CR Lee, J Wong, G Francia, RS Kerbel
Cancer research 66 (7), 3386-3391, 2006
2672006
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose …
U Emmenegger, S Man, Y Shaked, G Francia, JW Wong, DJ Hicklin, ...
Cancer research 64 (11), 3994-4000, 2004
2002004
Targeted anti–vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
M Franco, S Man, L Chen, U Emmenegger, Y Shaked, AM Cheung, ...
Cancer research 66 (7), 3639-3648, 2006
1742006
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
R Buckstein, RS Kerbel, Y Shaked, R Nayar, C Foden, R Turner, CR Lee, ...
Clinical cancer research 12 (17), 5190-5198, 2006
1622006
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy
Y Shaked, U Emmenegger, G Francia, L Chen, CR Lee, S Man, ...
Cancer research 65 (16), 7045-7051, 2005
1562005
The pro-tumorigenic host response to cancer therapies
Y Shaked
Nature Reviews Cancer 19 (12), 667-685, 2019
1532019
Copper binding to PrPC may inhibit prion disease propagation
N Hijazi, Y Shaked, H Rosenmann, T Ben-Hur, R Gabizon
Brain research 993 (1-2), 192-200, 2003
1362003
The system can't perform the operation now. Try again later.
Articles 1–20